In last trading session, Twist Bioscience Corp (NASDAQ:TWST) saw 0.8 million shares changing hands with its beta currently measuring 1.86. Company’s recent per share price level of $43.60 trading at -$1.52 or -3.37% at ring of the bell on the day assigns it a market valuation of $2.60B. That closing price of TWST’s stock is at a discount of -39.68% from its 52-week high price of $60.90 and is indicating a premium of 37.13% from its 52-week low price of $27.41. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.56 million shares which gives us an average trading volume of 776.38K if we extend that period to 3-months.
For Twist Bioscience Corp (TWST), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.77. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.63 in the current quarter.
Twist Bioscience Corp (NASDAQ:TWST) trade information
Upright in the red during last session for losing -3.37%, in the last five days TWST remained trading in the red while hitting it’s week-highest on Tuesday, 01/07/25 when the stock touched $43.60 price level, adding 15.03% to its value on the day. Twist Bioscience Corp’s shares saw a change of -6.18% in year-to-date performance and have moved -3.77% in past 5-day. Twist Bioscience Corp (NASDAQ:TWST) showed a performance of -15.59% in past 30-days. Number of shares sold short was 9.02 million shares which calculate 15.97 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 46 to the stock, which implies a rise of 5.22% to its current value. Analysts have been projecting 46 as a low price target for the stock while placing it at a high target of 46. It follows that stock’s current price would drop -5.5% in reaching the projected high whereas dropping to the targeted low would mean a loss of -5.5% for stock’s current value.
Twist Bioscience Corp (TWST) estimates and forecasts
Statistics highlight that Twist Bioscience Corp is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -16.92% of value to its shares in past 6 months, showing an annual growth rate of 36.94% while that of industry is 16.50. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 19.18% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 86.95M for the same. And 9 analysts are in estimates of company making revenue of 90.7M in the next quarter. Company posted 71.5M and 75.3M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.70% during past 5 years.
Twist Bioscience Corp (NASDAQ:TWST)’s Major holders
Insiders are in possession of 1.94% of company’s total shares while institution are holding 110.12 percent of that, with stock having share float percentage of 112.30%. Investors also watch the number of corporate investors in a company very closely, which is 110.12% institutions for Twist Bioscience Corp that are currently holding shares of the company. ARK INVESTMENT MANAGEMENT LLC is the top institutional holder at TWST for having 6.13 million shares of worth $302.06 million. And as of 2024-06-30, it was holding 10.5415 of the company’s outstanding shares.
The second largest institutional holder is ARTISAN PARTNERS LIMITED PARTNERSHIP, which was holding about 6.07 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.4371 of outstanding shares, having a total worth of $299.06 million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 3.2 shares of worth $139.49 million or 5.39% of the total outstanding shares. The later fund manager was in possession of 2.34 shares on Nov 30, 2024 , making its stake of worth around $102.15 million in the company or a holder of 3.95% of company’s stock.
